Who Owns Prolia?
Prolia (denosumab) is a biologic osteoporosis medication owned by Amgen Inc. (Nasdaq: AMGN), the biotechnology company headquartered in Thousand Oaks, California. Approved in 2010, it is the leading injectable osteoporosis treatment, administered as a twice-yearly injection to build bone density and reduce fracture risk. Parent FY2025 revenue was $36.8 billion.
Parent Company
Founded
2010
Status
Publicly Traded
Headquarters
Prolia Timeline
Who Owns Prolia?
- Parent Company: Amgen Inc.
- Ownership Type: Brand division
- Company Type: Publicly Traded
- Stock Ticker: NASDAQ: AMGN
| Brand | Parent Company | Ownership Type |
|---|---|---|
| Prolia | Amgen Inc. | Brand division |
Where to Buy
Disclosure: We may earn commission from purchases
Prolia on AmazonHistory of Prolia
- Founded: 2010
- Founders: Amgen (developer)
Amgen developed denosumab, a monoclonal antibody targeting RANK ligand to inhibit bone resorption, and won FDA approval as Prolia in 2010 for postmenopausal osteoporosis. The same molecule received approval as Xgeva for cancer-related bone events.
Prolia established itself as the leading injectable osteoporosis treatment, replacing bisphosphonates for many patients through superior fracture prevention and convenient twice-yearly dosing versus the oral agents' daily or weekly regimens.
Additional indications expanded the label to include glucocorticoid-induced osteoporosis, osteoporosis in men, and bone loss in patients on hormone-suppressing cancer treatments, broadening the addressable patient population.
The brand's growth has made it one of Amgen's largest and fastest-growing products, with sales exceeding $4 billion annually and consistent double-digit growth as global osteoporosis treatment penetration increases.
About Amgen Inc.
What does Amgen own?
Amgen owns the Amgen brand and product brands including Enbrel, Prolia, Otezla, Neulasta, Repatha, Tezspire, and others. The Horizon acquisition added Tepezza, Krystexxa, and Uplizna.
Is Amgen publicly traded?
Yes. Amgen trades on Nasdaq under ticker AMGN and is a component of the S&P 500 and Dow Jones Industrial Average.
Who founded Amgen?
George Rathmann founded Applied Molecular Genetics in 1980 in Thousand Oaks, California. The name Amgen derives from the original.
Where is Amgen headquartered?
Amgen is headquartered in Thousand Oaks, California, USA.
Who owns Amgen?
Amgen is owned by public shareholders with no controlling investor. Robert Bradway serves as Chairman and CEO.
What is Amgen's revenue?
Amgen reported FY2025 total revenues of $36.8 billion, up 10%, with GAAP net income of $7.7 billion and non-GAAP EPS of $21.84.
What does Amgen make?
Amgen makes biologic medicines including Enbrel for rheumatoid arthritis, Prolia for osteoporosis, Otezla for psoriasis, and oncology and rare disease treatments.
- Founded: 1980
- Headquarters: Thousand Oaks, California, USA
- Company Type: Publicly Traded
- Stock: NASDAQ: AMGN
- Revenue: $36.8 billion (FY2025)
- Employees: Approximately 28,000
Where Is Prolia Made / Based?
- Headquarters: Thousand Oaks, California, USA (parent)
- Manufacturing / Operations: United States, Ireland
Prolia Categories & Tags
Prolia Recalls & Controversies
As a pharmaceutical product, Prolia's issues are safety labeling and pricing rather than recalls.
Safety labeling: The drug carries warnings about hypocalcemia, osteonecrosis of the jaw, and atypical fractures, standard labeling for the class managed through prescribing guidance.
Discontinuation risk: Bone density losses can occur rapidly after stopping Prolia, creating guidance about treatment continuity that influences prescribing decisions.
Pricing: As a branded biologic, Prolia's US pricing faces the same affordability scrutiny affecting specialty pharmaceuticals broadly.
Brands Owned by Amgen Inc.
Healthcare PharmaceuticalsAmgen
Owned by Amgen Inc.
Master biotechnology brand of Amgen Inc., the world's largest independent biotech, covering its full portfolio of biologic medicines.
biotechnologypharmaceuticalsbiologics
Healthcare PharmaceuticalsEnbrel
Owned by Amgen Inc.
Biologic medication for rheumatoid arthritis and autoimmune conditions, owned by Amgen Inc., one of the highest-selling drugs in pharmaceutical history.
pharmaceuticalsbiologicsrheumatoid-arthritis
Healthcare PharmaceuticalsNeulasta
Owned by Amgen Inc.
Biologic medication for chemotherapy-induced neutropenia owned by Amgen Inc., the leading white blood cell stimulator for cancer patients.
pharmaceuticalsbiologicsoncology
Healthcare PharmaceuticalsOtezla
Owned by Amgen Inc.
Oral medication for psoriasis and psoriatic arthritis owned by Amgen Inc., the leading non-injectable treatment in its class.
pharmaceuticalspsoriasispsoriatic-arthritis
Prolia Ownership: Pros & Cons
Advantages
- +Leading injectable osteoporosis treatment globally
- +Twice-yearly dosing provides adherence advantage over oral agents
- +Undertreated osteoporosis market provides secular growth
- +Exceeds $4 billion in annual sales with continued growth
- +Backed by Amgen's biologics manufacturing and commercial scale
Considerations
- -Patent expiration approaches with biosimilar development underway
- -Discontinuation effects require treatment continuity management
- -Injectable delivery limits adoption versus oral alternatives for some patients
- -Pricing pressure from IRA and international negotiations
- -Competes with multiple treatment options in osteoporosis
Frequently Asked Questions About Prolia
Sources & Further Reading
Competitors to Prolia
These competing brands operate in the same categories and provide similar products or services. Compare key attributes to understand market positioning and competitive landscape.
| Brand | Parent Company | Country | Founded | Market Position | Primary Market | Gender Target |
|---|---|---|---|---|---|---|
| Amgen | USA | 1980 | Market leader | Global | All-ages | |
| Amgen | USA (parent) | 1998 | Market leader | Global | All-ages | |
| Amgen | USA (parent) | 2002 | Market leader | Global | All-ages | |
| Amgen | USA (parent) | 2014 | Market leader | Global | All-ages | |
| Teva | Israel | 1901 | Leader | Global | All Genders |
Learn More About Competitors
Healthcare PharmaceuticalsAmgen
Owned by Amgen Inc.
Master biotechnology brand of Amgen Inc., the world's largest independent biotech, covering its full portfolio of biologic medicines.
biotechnologypharmaceuticalsbiologics
Healthcare PharmaceuticalsEnbrel
Owned by Amgen Inc.
Biologic medication for rheumatoid arthritis and autoimmune conditions, owned by Amgen Inc., one of the highest-selling drugs in pharmaceutical history.
pharmaceuticalsbiologicsrheumatoid-arthritis
Healthcare PharmaceuticalsNeulasta
Owned by Amgen Inc.
Biologic medication for chemotherapy-induced neutropenia owned by Amgen Inc., the leading white blood cell stimulator for cancer patients.
pharmaceuticalsbiologicsoncology
Healthcare PharmaceuticalsOtezla
Owned by Amgen Inc.
Oral medication for psoriasis and psoriatic arthritis owned by Amgen Inc., the leading non-injectable treatment in its class.
pharmaceuticalspsoriasispsoriatic-arthritis
Healthcare PharmaceuticalsTeva Pharmaceuticals
Owned by Teva Pharmaceutical Industries
Israeli multinational pharmaceutical company and the world's largest generic drug manufacturer, publicly traded on NYSE under ticker TEVA, headquartered in Tel Aviv, Israel.
generic-drugspharmaceuticalsspecialty-medicines
Competitive Analysis
Market Positioning: Prolia competes with 5 brands in the same categories, ranging from mass market to luxury positioning.
Geographic Distribution: Competitors are headquartered across multiple regions, indicating global competition in this market segment.
Brand Heritage: Competitor brands range from established heritage brands to newer market entrants, with founding years spanning several decades.
Independent Alternatives to Prolia
Looking for brands with different ownership structures? These similar brands are not owned by Amgen Inc., giving you alternative choices that support different corporate structures.
Healthcare PharmaceuticalsNovo Nordisk
Owned by Novo Nordisk
Danish pharmaceutical company specializing in diabetes care and obesity treatment. Founded in 1923, headquartered in Bagsvaerd, Denmark. World leader in diabetes care and a leader in obesity treatment with Ozempic, Wegovy, and the investigational CagriSema. CEO Lars Fruergaard Jorgensen departed in March 2025; interim leadership under board chairman Helge Lund until a permanent CEO is appointed.
pharmaceuticalsdiabetesobesity
Publicly Traded
Novo Nordisk operates independently without a large parent corporation.
Healthcare PharmaceuticalsStryker
Owned by Stryker Corporation
Flagship medical technology brand of Stryker Corporation, founded in 1941 and a global leader in orthopaedic implants and surgical equipment.
medical-devicesorthopaedicssurgical-equipment
Publicly Traded
Stryker operates independently without a large parent corporation.
Healthcare PharmaceuticalsHCA Healthcare
Owned by HCA Healthcare, Inc.
HCA Healthcare is the flagship brand of the largest U.S. for-profit hospital operator, a network of 190 hospitals and about 2,500 ambulatory sites across 19 states and England.
hospitalshealthcareemergency-care
Publicly Traded
HCA Healthcare operates independently without a large parent corporation.
Healthcare PharmaceuticalsPfizer
Owned by Pfizer Inc.
American multinational pharmaceutical corporation developing and manufacturing medicines, vaccines, and consumer healthcare products, one of the world's largest pharmaceutical companies.
pharmaceuticalvaccinesmedicines
Publicly Traded
Pfizer operates independently without a large parent corporation.
Healthcare PharmaceuticalsWalgreens
Owned by Walgreens Boots Alliance
Walgreens is the largest U.S. pharmacy retail brand, operating roughly 8,000 stores. It went private in August 2025 under Sycamore Partners as a standalone company.
pharmacydrugstoreretail-pharmacy
Privately Owned
Walgreens is privately owned, unlike Prolia which is under a publicly traded parent company.
Healthcare PharmaceuticalsAlcon
Owned by Alcon Inc.
Independent publicly traded global eye care company headquartered in Geneva, Switzerland, specializing in surgical equipment, contact lenses, and ophthalmic products. Spun off from Novartis in April 2019.
eye-carecontact-lensesophthalmic
Publicly Traded
Alcon operates independently without a large parent corporation.
Amgen Inc. Stock Information
Jobs at Amgen Inc.
Latest News About Prolia
Related Articles About Prolia
View more articles
Brand Comparisons
Pfizer vs Johnson & Johnson: Pharma Brand Portfolios Compared
Pfizer and Johnson & Johnson are two of the most recognizable names in healthcare. But their brand portfolios look nothing alike. Here is a complete breakdown of what each company owns, how they got there, and what sets them apart.
Who Brands StaffMar 16, 2026
PharmaceuticalPfizerJohnson And Johnson
Brand Ownership
15 Pharmacy Brands and Their Corporate Parents
CVS spent $69 billion to buy Aetna. Walgreens acquired Boots for $15 billion. Amazon paid $1 billion for PillPack. Here are 15 pharmacy brands, who owns them, and how a once-diverse industry collapsed into two dominant players.
Who Brands StaffFeb 26, 2026
Pharmacy BrandsBrand OwnershipCvs
Brand Ownership
Who Owns Your Vitamins? The Hidden Corporate Parents Behind Supplement Brands
The supplement industry is worth $60+ billion but most brands are owned by pharma giants and food conglomerates. Here is who owns every major vitamin and supplement brand.
Who Brands StaffFeb 5, 2026
VitaminsSupplementsBrand Ownership
People Also Searched
Discover popular brands and companies in the Healthcare & Pharmaceuticals category and related searches from other users.
Brandpharmaceutical
Abbokinase
Abbokinase (urokinase) is a thrombolytic medication historically used for pulmonary embolism and catheter clearance. Originally marketed by Abbott Laboratories, now owned by Microbix Biosystems as Kinlytic. FDA-approved since 1978.
Brand in Healthcare & Pharmaceuticals
thrombolyticurokinase
Brandrsv-vaccine
Abrysvo
Pfizer's respiratory syncytial virus (RSV) vaccine approved for older adults, maternal immunization to protect infants, and younger at-risk adults. Launched 2023.
Brand in Healthcare & Pharmaceuticals
vaccinesmaternal-immunization
Branddermatology
Accutane
Prescription isotretinoin brand developed by Roche and approved by the FDA in 1982 for severe nodular acne. Roche discontinued the brand name in the United States in 2009; the drug continues as Roaccutane in international markets.
Brand in Healthcare & Pharmaceuticals
acne-treatmentprescription